KIF5B-RET融合基因在非小细胞肺癌中的研究进展

Research Progress on KIF5B-RET Fusion Gene in Non-small Cell Lung Cancer

KIF5B-RET融合基因存在于部分非小细胞肺癌(NSCLC)中,是除EGFR、k-ras、EML4-ALK驱动基因之外另一个重要的酪氨酸激酶抑制剂作用靶点。该融合基因在不吸烟或少量吸烟、腺癌、无EGFR及k-ras突变、无EML4-ALK融合基因的NSCLC患者中发生率较高,并且对RET抑制剂(如凡德他尼)有较好的治疗反应。全文就KIF5B-RET融合基因的基本结构、功能、检测及其在NSCLC中的研究进展进行综述。

KIF5B-RET fusion gene presents in some non-small cell lung cancer（NSCLC）,which is another important molecular target of tyrosine kinase inhibitors in addition to EGFR,k-ras and EML4-ALK driving genes. This fusion gene has a higher morbidity rate in NSCLC patients with no or light smoking history,with adenocarcinoma,without EGFR and k-ras mutations and without EML4-ALK fusion gene. They have shown good response to RET inhibitors,such as vandetanib. In this paper,basic structure,function,detection and research advance of KIF5BRET fusion gene are reviewed.